Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2005 / N 3

Статины и ревматические заболевания – новый взгляд на проблему (список литературы)
Н.А. Шостак, Д.А. Аничков

Литература
1. Simons LA, Sullivan DR. Lipid-modifying drugs. Med J Aust. 2005; 182(6): 286-289.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994; 344: 1383-1389.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
5. Garcia PJ. Pleiotropic effects of statins: moving beyond cholesterol control. Curr Atheroscler Rep. 2005; 7(1): 34-39.
6. Fenton JW 2nd, Jeske WP, Catalfamo JL, Brezniak DV, Moon DG, Shen GX: Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc) 2002, 67: 85-91.
7. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999; 340: 115-126.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12): 836-843.
9. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999; 100(21): 2124-2126.
10. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis. 2000; 59(5): 321-325.
11. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108(24): 2957-2963.
12. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002; 162: 179-185.
13. Wagner AH, Gebauer M, Guldenzoph B, Hecker M: 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1784-1789.
14. Inoue I, Goto S, Mootani K, et al. Lipophilic HMG–CoA reductase inhibitor has an anti–inflammatory effect: reduction of MRNA levels for interleukin–1 beta, interleukin–6. cyclooxygenase–2, and p22phox by regulation of peroxisome proliferator–activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000: 67: 863–876.
15. Насонов ЕЛ. Перспективы применения статинов в ревматологии. РМЖ 2003; 11(23): 1273-1276.
16. McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther. 2005; 7(2): 55-61.
17. Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003; 170(3): 1524-1530.
18. Palmer G, Chobaz V, Talabot-Ayer D, et al. Assessment of the efficacy of different statins in murine collagen-induced arthritis. Arthritis Rheum. 2004; 50(12): 4051-4059.
19. Farzaneh-Far A, Roman MJ. Accelerated atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Pract. 2005; 59(7): 823-824.
20. Bijl M. Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases. Neth J Med. 2003; 61(9): 273-277.
21. del Rincon I, Escalante A. Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep. 2003; 5(4): 278-286.
22. Roman MJ, Salmon JE, Sobel R, et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol. 2001; 87(5): 663-666.
23. Шостак НА, Махнырь ЕФ, Голоухова ЛМ. Ревматоидная болезнь сердца: клинико-инструментальные параллели и новые перспективы лечения. Фарматека 2005; 8: 50-53.
24. Anichkov DA, Shostak NA, Ivanov DS. Determinants of left ventricular remodeling in rheumatoid arthritis patients [abstract AB0094]. EULAR 2005 Congress; 2005 June 8-11; Vienna. Available from URL: http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2005SCIE-abstract&TEMPLATE=&keyf=2364
25. del Rincon I, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745.
26. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early seropositive polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rhem 2002; 46: 2010-2019.
27. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307.
28. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005; 52(2): 402-411.
29. Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005; 7: R984-R991.
30. Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
31. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
32. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408-415.
33. Kanda H, Hamasaki K, Kubo K, et al. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol. 2002; 29(9): 2024-2026.
34. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003; 12(8): 607-611.
35. Попкова ТВ, Алекберова ЗС, Александрова ЕН, Насонов ЕЛ. Опыт применения ловастатина у пациентов с системной красной волчанкой и ревматоидным артритом. РМЖ 2005; 13(7): 400-402.
36. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004; 363: 2015-2021.
37. Klareskog L, Hamsten A. Statins in rheumatoid arthritis--two birds with one stone? Lancet. 2004; 363: 2011-2012.
38. Van Doornum S, McColl G, Jenkins A, et al. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum. 2003; 48(1): 72-80.
39. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002; 22: 1637-1641.
40. Hansel S, Lassig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis. 2003; 170(1): 177-180.
41. Vaudo G, Marchesi S, Gerli R, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis. 2004; 63(1): 31-35.
42. Wong M, Toh L, Wilson A, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum. 2003; 48(1): 81-89.
43. Klocke R, Cockcroft JR, Taylor GJ, et al. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Ann Rheum Dis. 2003; 62(5): 414-418.
44. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000; 102(8): 846-851.
45. Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol. 2001; 38(3): 814-818.
46. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2004; 63(12): 1571-1575.
47. Hermann F, Forster A, Chenevard R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol. 2005; 45(3): 461-464.
48. Hürlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-2187.
49. Ahmad S. Lovastatin-induced lupus erythematosus. Arch Intern Med. 1991; 151(8): 1667-1668.
50. Jimenez-Alonso J, Jaimez L, et al. Atorvastatin-induced reversible positive antinuclear antibodies. Am J Med. 2002; 112(4): 329-330.
51. Савенков МП. Применение статинов: необходимость возрастает, выбор и доступность увеличиваются. Атмосфера. Кардиология. 2004; 3: 21-23.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]